The Double‐Blind Placebo‐Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine‐Containing Regimen for Prevention of High‐Dose Cisplatin‐Induced Nausea/Vomiting
In this Phase II trial, there was no significant improvement in overall CR when patients received upfront netupitant compared to subsequent addition of netupitant to an olanzapine regimen in patients receiving high-dose cisplatin chemotherapy.
Authors
- Suebpong Tanasanvimon (ORCID: https://orcid.org/0000-0002-3904-4719)
- Attapol Chotirut (ORCID: https://orcid.org/0000-0003-3038-0510)
- Chalermchai Lertanansit
- Piyada Sitthideatphaiboon (ORCID: https://orcid.org/0000-0003-2098-1646)
- Nicha Zungsontiporn
- Wasamol Mahaparn
- Chanida Vinayanuwattikun (ORCID: https://orcid.org/0000-0003-3622-7752)
- Nattaya Sintawichai
- Virote Sriuranpong
- Suleepon Uttamapinan
Institutions
- Chulalongkorn University (TH)
- Bangkok Hospital (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Surin Hospital (TH)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1111/ajco.14192
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00